N@N

Market Maker Surveillance Report. GRYO, ACTC, KG, ARNA, S, CIM, Highest Net Sell Volume and Negative Price Friction For Wednes

^{Published on 2010-12-22 19:01:48 - WOPRAI}
 

December 22, 2010 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 2666 companies with "abnormal" market making, 2936 companies with positive Friction Factors and 2462 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Wednesday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. GRYPHON RESOURCES INC (OTC:GRYO), ADVANCED CELL TECHNOLOGY INC (OTCBB:ACTC), KING PHARMACEUTICALS INC (NYSE:KG), ARENA PHARMACEUTICALS INC (NASDAQ:ARNA), SPRINT NEXTEL CORP (NYSE:S), CHIMERA INVESTMENT CORP (NYSE:CIM). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     GRYO       $-0.010      -8.70%       1,416,292       21.23%       4,777,230       71.62%       -3,360,938      -3,360,938
     ACTC       $-0.033      -12.60%      31,710,042      44.28%       37,128,631      51.84%       -5,418,589      -1,641,997
     KG         $-0.030      -0.21%       3,270,299       37.66%       4,931,269       56.78%       -1,660,970      -553,657
     ARNA       $-0.230      -11.27%      14,243,349      43.88%       18,189,245      56.03%       -3,945,896      -171,561
     S          $-0.100      -2.32%       11,818,120      41.41%       14,959,239      52.42%       -3,141,119      -314,112
     CIM        $-0.040      -0.94%       7,841,961       35.30%       13,126,604      59.09%       -5,284,643      -1,321,161

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have low price friction combined with more selling than buying (negative Net Volume) in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows CIM down $-0.04000 with a Friction Factor of -1,321,161 and a Net Volume of -5,284,643. That means that it takes 1,321,161 more shares of selling than buying to drop CIM by one penny. On Monday the Market Makers allowed the stock to move down on heavier selling than buying (low negative friction).

GRYPHON RESOURCES INC (OTC:GRYO) - Gryphon Resources, Inc. operates as a mineral exploration company. It focuses on mineral exploration opportunities in Turkey. The company was formerly known as Gryphon Oil & Gas Inc. and changed its name to Gryphon Resources, Inc. in August 2006. Gryphon Resources, Inc. was founded in 2006 and is based in Bellingham, Washington.

ADVANCED CELL TECHNOLOGY INC (OTCBB:ACTC) - Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. It primarily focuses on cellular reprogramming, reduced complexity program, and stem cell differentiation research programs. The companys cellular reprogramming involves in the development of therapies based on the use of genetically identical pluripotent stem cells generated by its cellular reprogramming technologies. Advanced Cell Technology, Inc. is also generating stable cell lines with particular focus on blood lineage and vascular epithelial cell lines from hemangioblast cells. In addition, it is developing an autologous myoblast transplantation therapy to restore cardiac function in patients with advanced heart disease. The companys stem cell-based therapy would provide treatment for a range of acute and chronic degenerative diseases. Further, it develops adult stem cell-based products that are specifically targeted at therapies for heart and other cardiovascular diseases. The company is headquartered in Worcester, Massachusetts.

KING PHARMACEUTICALS INC (NYSE:KG) - King Pharmaceuticals, Inc. research and develops, manufactures, markets, and sells branded prescription pharmaceutical products and animal health products worldwide. It offers branded prescription pharmaceuticals, which include neuroscience products, such as Skelaxin, Flector Patch, Avinza, and Embeda; hospital products, including Thrombin-JMI; and legacy products consisting of Levoxyl, Bicillin, Altace, and Cytomel to general/family practitioners, internal medicine physicians, neurologists, pain specialists, surgeons, and hospitals. The companys animal health business focuses on medicated feed additives and water-soluble therapeutics, which are anti-infective products primarily for poultry, cattle, and swine markets. King Pharmaceuticals also manufactures and markets pharmaceutical products that are delivered using an auto-injector to commercial and government markets. Its auto-injector products include EpiPen, an auto-injector filled with epinephrine for the treatment of anaphylaxis resulting from severe or allergic reactions to insect stings or bites, foods, drugs, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; the nerve agent antidotes, including AtroPen and ComboPen; and the Antidote Treatment Nerve Agent Auto-injector. The company also licenses rights to third-party pharmaceutical companies to manufacture and market adenosine-based products, Adenoscan. Adenoscan is a sterile, intravenous solution of adenosine administered intravenously as an adjunct to imaging agents used in cardiac stress testing of patients. King Pharmaceuticals distributes its branded pharmaceutical products through wholesale pharmaceutical distributors, as well as animal health products through sales force. The company was founded in 1993 and is based in Bristol, Tennessee.

ARENA PHARMACEUTICALS INC (NASDAQ:ARNA) - Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company also discovers small molecule drug candidates that target G protein-coupled receptors (GPCRs). Its clinical development programs include lorcaserin that has completed Phase III clinical trials for the treatment of weight management; APD791, an anti-thrombotic drug candidate, which completed Phase Ia and Phase Ib clinical trials; APD597 that is in Phase I clinical trials for the treatment of type II diabetes; APD916, which has completed preclinical development for the treatment of narcolepsy and cataplexy; and APD811, a preclinical drug candidate for the treatment of pulmonary arterial hypertension. The companys drug candidates use GPCR-focused drug discovery and development approach, as well as technologies, including Constitutively Activated Receptor Technology and Melanophore Technology. It has collaboration agreements with Ortho-McNeil-Janssen Pharmaceuticals, Inc. to further develop compounds for the potential treatment of type II diabetes and other disorders; and Merck & Co., Inc. to develop therapeutics for atherosclerosis and other disorders. Arena Pharmaceuticals also has a strategic cooperation agreement with Siegfried Ltd to manufacture lorcaserin. The company was founded in 1997 and is based in San Diego, California.

SPRINT NEXTEL CORP (NYSE:S) - Sprint Nextel Corporation offers wireless and wireline communications products and services to consumers, businesses, and government users in the United States, Puerto Rico, and the U.S. Virgin Islands. Its Wireless segment provides wireless mobile voice and data transmission services on networks that utilize CDMA and iDEN technologies, as well as offers fourth generation wireless services. Its wireless data communications services comprise Internet access and messaging, email services, wireless photo and video offerings, and mobile entertainment applications, as well as asset and fleet management, dispatch services, and navigation tools; and wireless voice communications services include basic local and long distance wireless voice services, voicemail, call waiting, three way calling, caller identification, directory assistance, call forwarding, speakerphone, and push-to-talk services, as well as roaming services. This segment sells accessories, such as carrying cases, hands-free devices, batteries, and battery chargers, as well as devices and accessories to agents and other third-party distributors for resale. In addition, it markets its post-paid services under the Sprint and Nextel names; prepaid services under the Boost Mobile, Virgin Mobile, and Assurance Wireless names. The companys Wireline segment provides wireline voice and data communications services, including domestic and international data communications using various protocols, such as multiprotocol label switching technologies, Internet protocol (IP), asynchronous transfer mode, IP-based frame relay, managed network services, voice over IP, and traditional voice services. It also offers wide-area network and long distance services, as well as operates an all-digital long distance and Tier 1 IP network. Sprint Nextel was founded in 1899 and is headquartered in Overland Park, Kansas.

CHIMERA INVESTMENT CORP (NYSE:CIM) - Chimera Investment Corporation, a real estate investment trust, invests in residential mortgage backed securities (RMBS), residential mortgage loans, real estate-related securities, asset backed securities (ABS), and various other asset classes in the United States. It invests in agency and non-agency RMBS; whole mortgage loans comprising prime, jumbo prime, and Alt-A mortgage loans; and ABS, including debt and equity tranches of CDOs, consumer and non-consumer ABS, and commercial mortgage backed securities. The company has elected to be treated as a REIT for federal income tax purposes and would not be subject to income tax, if it distributes at least 90% of its REIT taxable income to its share holders. Chimera Investment Corporation was incorporated in 2007 and is based in New York, New York.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net